Other studies have revealed that the presence of mutations in the PIK3 gene, seen in 12 to 39% of HER2-positive BC patients, can lead to resistance to trastuzumab therapy, showing a lower pCR rate and shorter disease-free survival [18]. Here, PIK3CG is linked to breast cancer.